A real-world data study confirms the effects of GLP-1 therapy delivered via digital platform

A study published on October 16 in Nature Medicine, authored by John Deanfield, Jamie Lai Chun Wong and Donna H. Ryan, analyzed a cohort of 8,127 women in the United Kingdom who had started therapy with GLP-1 receptor agonists through a digital platform.

Six months after starting therapy, the cohort showed an average weight reduction comparable to that observed in randomized clinical trials of the same type of drug. This is the central finding of the study: a result achieved outside the controlled setting of a clinical trial, under conditions of everyday use through a digital service.

The main limitation of the research concerns precisely its nature: this is an observational study using real-world data, not a randomized controlled trial. The comparison with the results of clinical trials is therefore descriptive and does not amount to a demonstration of statistical equivalence between the two contexts. The population analyzed, moreover, consists exclusively of women in the United Kingdom, a sample that does not allow the results to be generalized to other populations or other healthcare systems, and the observation period is limited to six months, a timeframe that says nothing about longer-term effects.

The study does not provide indications on dosages, prescribing methods or usage recommendations: it describes an outcome observed in a population that had already started a prescribed treatment, delivered through a digital monitoring platform. No information emerges from the available excerpts regarding any conflicts of interest declared by the authors in the published study.

What remains, net of the stated limitations, is that a treatment delivered outside the traditional clinical setting produced, in a cohort of more than eight thousand people, results in the same direction as those measured in randomized trials.